CMPXSeeking Alpha·April 27, 2026 at 05:51 PM

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript

Source: Seeking Alpha

CMPXCompass Therapeutics, Inc.

$1.88 – $2.15

View CMPXdetails →